Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25

In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1. Safety (CTCAE v4.03) and QoL (EORT...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2024-12
Main Authors: Montégut, Coline, Falandry, Claire, Cinieri, Saverio, Cropet, Claire, Montane, Laure, Rousseau, Frédérique, Joly, Florence, Moubarak, Malak, Mosconi, Anna M, Guerra-Alía, Eva M, Schauer, Christian, Fujiwara, Hiroyuki, Vergote, Ignace, Parma, Gabriella, Lindahl, Gabriel, Anota, Amélie, Canzler, Ulrich, Marmé, Frederik, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Sabatier, Renaud
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1. Safety (CTCAE v4.03) and QoL (EORTC QoL Questionnaires Core 30 and Ovarian 28) data were collected. We compared safety by age (≥70 vs 
ISSN:1549-490X
1549-490X
DOI:10.1093/oncolo/oyae322